Floatz logo

Mb-Cart2019.1

Pediatric ALL

Miltenyi Biomedicine GmbHN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

70 Active assets in the Pediatric ALL cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 3BBB
MERCAPTOPURINE ANHYDROUS
Children's Oncology Group
Phase 3BBB
Cytosin-Arabinosid
Children's Oncology Group
Phase 3BBB
METHOTREXATE
Children's Oncology Group
Phase 3BBB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 3BBB

View all 50 →

Same molecule, other indications

Mb-Cart2019.1 is also rated in:

CAR T Cell TherapyDormant
B
Indicative ·
60 / 100
View asset →
diffuse large B-cell lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →